Genmab A/S (GNMSF) Depreciation and Depletion (2024 - 2026)

Genmab A (GNMSF) has 3 years of Depreciation and Depletion data on file, last reported at $16.0 million in Q1 2026.

• Quarterly Depreciation and Depletion rose 33.33% year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.0 million (up 12.2% YoY) and the FY2025 annual result came in at $55.0 million, up 12.24% from the prior year.
• Depreciation and Depletion slipped to $16.0 million in Q1 2026, from $39.0 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $39.0 million in Q3 2025 to a low of $11.0 million in Q1 2024.
• A 3-year average of $23.1 million and a median of $23.0 million in 2024 frame the typical range for Depreciation and Depletion.
• Annual changes were most pronounced in 2025 — Depreciation and Depletion grew 8.33% — and 2026, when it jumped 33.33%.
• Tracing GNMSF's Depreciation and Depletion over 3 years: stood at $36.0 million in 2024, then climbed by 8.33% to $39.0 million in 2025, then slumped by 58.97% to $16.0 million in 2026.
• The last three Depreciation and Depletion figures came in at $16.0 million (Q1 2026), $39.0 million (Q3 2025), and $25.0 million (Q2 2025), per Business Quant data.